Outcome of board of SMS Lifesciences India

Image
Capital Market
Last Updated : Feb 08 2018 | 10:04 PM IST

Held on 08 February 2018

The Board of SMS Lifesciences India at meeting held on 08 February 2018 has agreed inprinciple for the acquisition of Mahi Drug, subject to conducting due-diligence.

Further, the Board has deliberated and deferred the issue of Non Convertible Preference shares or Non Convertible Debentures on preferential basis to the promoter or promoter group.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Feb 08 2018 | 9:44 PM IST

Next Story